Teriparatide
The active first 34 amino acids of parathyroid hormone; daily injections stimulate new bone formation.
FDA-approved as Forteo for osteoporosis.
Look it up on Wikipedia9 listings across 7 independently tested vendors, ranked by price per milligram after coupon codes anyone can use. Vendors you can only order from by message are hidden.
Some links here are affiliate links: if you buy through one, this site may earn a commission at no extra cost to you. Prices, rankings and plans are worked out the same way whether or not a vendor pays one.
FDA-approved (Forteo and others) for osteoporosis.
Daily price tracking started October 7, 2026; a price-history chart appears here once a few days have been collected.
| Vendor | Trust | Listing | Vials | Price | Per mg | |
|---|---|---|---|---|---|---|
Andy Peps Studio #64 by metascore · China |
TER10 Teriparatide 10mg * 10 vials | 10 × 10 mg = 100 mg | $150.00 $15.00 per vial |
$1.50 | Buy | |
Baohua Dongnuo Biotechnology BHD #77 by metascore · China |
TER10 Teriparatide 10mg * 10 vials | 10 × 10 mg = 100 mg | $150.00 $15.00 per vial |
$1.50 | Buy | |
LN Peptides #254 by metascore · China |
Metascore 71Finnrick 72%Bought vials 99% of label · 39 testsTitrateLabNo report for thisOnline checkout |
TER10 Teriparatide 10mg * 10 vials | 10 × 10 mg = 100 mg | $150.00 $15.00 per vial |
$1.50 | Buy |
BeiBangAn #28 by metascore · China |
TER10 Teriparatide 10mg * 10 vials | 10 × 10 mg = 100 mg | $150.00 $15.00 per vial |
$1.50 | Buy | |
Qingdao Sigma Chemical QSC #69 by metascore |
Teriparatide 10mg | 20-Vial Kit | PTH 1-34 Fragment / Anabolic Bone Peptide | 20 × 10 mg = 200 mg | $610.00 $30.50 per vial |
$3.05 | Buy | |
Qingdao Sigma Chemical QSC #69 by metascore |
Teriparatide 10mg | 10-Vial Kit | PTH 1-34 Fragment / Anabolic Bone Peptide | 10 × 10 mg = 100 mg | $330.00 $33.00 per vial |
$3.30 | Buy | |
Uther #62 by metascore · China |
Metascore 79Finnrick 64%Bought vials 105% of label · 73 testsTitrateLabNo report for thisOnline checkout |
Teriparatide 750mcg (10 Vials / Kit) | 10 × 750 mcg = 7.5 mg | $100.00 $10.00 per vial |
$13.33 | Buy |
Atomik Labz Affiliate #85 by metascore · US. Florida, 33411 |
Metascore 77Finnrick 69%Bought vials 112% of label · 44 testsTitrateLab · Peptide CriticNo report for thisOnline checkoutCheck vendor |
Teriparatide 1mg Ten Pack | 10 × 1 mg = 10 mg | $1,260.00 $126.00 per vial |
$126.00 | Buy |
Atomik Labz Affiliate #85 by metascore · US. Florida, 33411 |
Metascore 77Finnrick 69%Bought vials 112% of label · 44 testsTitrateLab · Peptide CriticNo report for thisOnline checkoutCheck vendor |
Teriparatide 1mg | 1 × 1 mg | $130.00 | $130.00 | Buy |
Mixing a 10 mg vial
What each common amount of bacteriostatic water gives you on a U-100 insulin syringe. Pick a vial size above to change it.
| Water | Strength | Per 10 units (0.1 mL) | Per unit |
|---|---|---|---|
| 1 mL | 10 mg/mL | 1,000 mcg | 100 mcg |
| 2 mL | 5 mg/mL | 500 mcg | 50 mcg |
| 3 mL | 3.333 mg/mL | 333.3 mcg | 33.33 mcg |
| 5 mL | 2 mg/mL | 200 mcg | 20 mcg |
Doses studied in research Approved drug
What was given to people (or animals) in published studies and official labels, each linked to its source. This is not a recommendation: study products, purity and supervision differ from research-grade vials.
20 mcg subcutaneously once a day into the thigh or abdomen; use for more than 2 years in a patient's lifetime only considered if fracture risk remains or returns to high (subcutaneous)
Official label| Who was studied | Dose given | How often | For how long | What happened | |
|---|---|---|---|---|---|
| postmenopausal women with prior vertebral fractures (Neer et al.) n = 1637 |
20 or 40 microg parathyroid hormone (1-34) vs placebo subcutaneous | once daily | median 21 months | new vertebral fractures 5% and 4% vs 14% placebo (RR 0.35 and 0.31); nonvertebral fragility fractures 3% vs 6% | PubMed |
| postmenopausal women with severe osteoporosis and prior vertebral fractures (VERO, double-dummy vs risedronate) n = 1360 |
20 μg teriparatide (vs risedronate 35 mg weekly) subcutaneous | once daily | 24 months | new vertebral fractures 5.4% vs 12.0% with risedronate (RR 0.44); clinical fractures 4.8% vs 9.8% | PubMed |
| postmenopausal women with osteoporosis (ACTIVE phase 3; open-label teriparatide arm) n = 2463 |
teriparatide 20 μg (open-label) vs abaloparatide 80 μg or placebo subcutaneous | once daily | 18 months | new morphometric vertebral fractures less frequent in both active groups than placebo | PubMed |
| postmenopausal women with osteoporosis (DATA) n = 94 |
20 μg teriparatide, alone or with denosumab 60 mg every 6 months subcutaneous | once daily | 12 months | lumbar spine BMD +6.2% with teriparatide alone vs +9.1% combined | PubMed |
The approved US schedule is 20 mcg daily; a once-weekly regimen was studied in Japan. The former boxed warning for osteosarcoma (from rat studies) was removed after human registry data.
What the research says
Teriparatide (PTH 1-34) is an approved osteoporosis drug backed by large human randomized trials and multiple meta-analyses showing it reduces vertebral fractures and raises bone density, including head-to-head superiority over risedronate in severe osteoporosis. The rat osteosarcoma signal has not been borne out in large human registry studies, though more people stop treatment because of side effects than on placebo.
Key papers ✓ 7✗ 1
-
Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.Humanssize not reported34 RCTs pooledLiving systematic review and network meta-analysis for the American College of Physicians
Living network meta-analysis for the American College of Physicians (34 RCTs): teriparatide reduced clinical and radiographic vertebral fractures in postmenopausal women but increased withdrawals due to adverse events (moderate-to-high certainty).
Study details
- Studied
- Adults with low bone mass or primary osteoporosis
- Main outcome
- Fracture prevention and harms
- Sample
- 34 RCTs (100 publications) and 36 observational studies
- Authors' conclusion
- Bisphosphonates, denosumab, abaloparatide, teriparatide and romosozumab followed by alendronate reduce clinical fractures in postmenopausal women with osteoporosis; abaloparatide and teriparatide increased withdrawals due to adverse events.
- Limitations
- Few studies in low bone mass, males, Black-identifying persons, sequential therapy or treatment beyond 3 years.
-
Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials.Humans6,680 people23 trials pooledRandomized trialsTreatment cycles of over 12 monthsSystematic review and meta-analysis of head-to-head RCTs
Meta-analysis of 23 head-to-head RCTs (6,680 patients): teriparatide lowered fracture risk vs bisphosphonates (RR 0.61) and raised spine and hip bone density, with no overall increase in adverse events.
Key resultTeriparatide reduced fracture risk vs bisphosphonates (RR = 0.61, 95% CI 0.51-0.74, P < 0.001); denosumab showed no fracture benefit (RR 0.99, 95% CI 0.62-1.57, P = 0.96)
Study details
- Studied
- Patients with osteoporosis not previously treated with bisphosphonates
- Compared with
- Bisphosphonates
- Main outcome
- Fracture risk, bone mineral density, adverse events
- Sample
- 6680 patients across 23 randomized trials
- Authors' conclusion
- Teriparatide was superior to bisphosphonates in decreasing fracture risk, and teriparatide and denosumab both increased BMD more than bisphosphonates without more adverse events.
- Limitations
- Clinical heterogeneity between trials, handled with fixed- and random-effect models.
-
PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis.Humanssize not reported17 studies pooledSystematic review with pairwise meta-analysis and Bayesian network meta-analysis
Network meta-analysis of 11 RCTs and 6 real-world studies: teriparatide and abaloparatide both reduced vertebral and non-vertebral fractures vs placebo, with abaloparatide slightly better for non-vertebral and hip fractures; no increased cardiovascular risk.
Key resultAbaloparatide vs teriparatide: non-vertebral fractures OR 0.87 (95% CI 0.80-0.95), hip fractures OR 0.81 (95% CI 0.71-0.93)
Study details
- Studied
- Patients with osteoporosis in trials and real-world studies of PTH1 receptor agonists
- Compared with
- Abaloparatide, placebo and other osteoporosis treatments
- Main outcome
- Vertebral, non-vertebral, hip and all fractures; safety
- Sample
- 17 studies (11 RCTs, 6 real-world evidence studies)
- Authors' conclusion
- PTH1 receptor agonists effectively reduce fracture risk, with abaloparatide offering enhanced benefit over teriparatide for non-vertebral and hip fractures; both have acceptable safety.
- Limitations
- Mixes RCT and real-world data; the comparison of interest is teriparatide vs abaloparatide.
-
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.Humans680 patients in each groupRandomizedDouble-blind24 monthsMulticentre, double-blind, double-dummy randomised controlled trial (VERO)
VERO trial in 1,360 women with severe osteoporosis: new vertebral fractures at 24 months were 5.4% with teriparatide vs 12.0% with risedronate (RR 0.44); non-vertebral fractures did not differ significantly.
Key resultNew vertebral fractures in 28 (5·4%) of 680 with teriparatide vs 64 (12·0%) of 680 with risedronate (risk ratio 0·44, 95% CI 0·29-0·68; p<0·0001)
Study details
- Studied
- Post-menopausal women with severe osteoporosis (at least two moderate or one severe vertebral fracture)
- Compared with
- Risedronate 35 mg weekly
- Main outcome
- New radiographic vertebral fractures
- Authors' conclusion
- In post-menopausal women with severe osteoporosis, new vertebral and clinical fractures were significantly lower with teriparatide than risedronate.
- Limitations
- Non-vertebral fragility fracture difference was not significant (p=0·10); industry-funded.
-
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.Humans1,637 peopleRandomizedPlacebo-controlledMedian 21 months of observationRandomized trial of PTH (1-34) 20 or 40 microg daily subcutaneously
Pivotal trial in 1,637 postmenopausal women with prior vertebral fractures: daily PTH(1-34) reduced vertebral and non-vertebral fractures and raised spine bone density by 9-13 points vs placebo; side effects were minor (occasional nausea, headache).
Key resultNew vertebral fractures in 14 percent with placebo vs 5 percent (20 microg) and 4 percent (40 microg); relative risks 0.35 and 0.31
Study details
- Studied
- Postmenopausal women with prior vertebral fractures
- Compared with
- Placebo
- Main outcome
- New vertebral fractures and bone mineral density
- Sample
- 1637 postmenopausal women
- Authors' conclusion
- PTH (1-34) decreased vertebral and nonvertebral fracture risk, increased bone density and was well tolerated; the 40-microg dose had similar fracture effects but more side effects.
- Limitations
- Abstract does not state blinding details.
-
The Fracture Incidence and Safety of Teriparatide and Bisphosphonate in Postmenopausal Women With Osteoporosis: A Meta-Analysis.Humans3,376 people5 RCTs pooledMeta-analysis of randomized controlled trials
Meta-analysis of RCTs vs bisphosphonates in postmenopausal women: fewer new and clinical vertebral fractures with teriparatide; adverse events similar overall but dizziness was more frequent with teriparatide.
Key resultClinical vertebral fracture OR=1.97 (95% CI=1.43-2.73, P < .0001) and new vertebral fractures OR=2.44 (95% CI=1.70-3.50, P < .00001), both reduced more with teriparatide
Study details
- Studied
- Postmenopausal women with osteoporosis
- Compared with
- Bisphosphonates
- Main outcome
- Fracture incidence and adverse effects
- Sample
- 3376 participants in 5 RCTs
- Authors' conclusion
- Clinical and new vertebral fractures decreased more with teriparatide than bisphosphonate, but teriparatide had a higher rate of dizziness and of discontinuation due to adverse events.
- Limitations
- Only 5 RCTs included.
-
Assessing the incidence of osteosarcoma among teriparatide-treated patients using linkage of commercial pharmacy and state cancer registry data, contributing to the removal of boxed warning and other labeling changes.Humans18 osteosarcoma cases across four cohorts10-year periodObservational cohort study linking pharmacy dispensing data to state cancer registries
Ten-year US pharmacy/cancer-registry linkage study: osteosarcoma incidence in teriparatide users was within the expected background range (estimates imprecise), supporting removal of the boxed warning.
Key resultIncidence rate ratio 1.0 (95% CI: 0.2, 4.5) vs osteoporosis and 1.3 (95% CI: 0.2, 5.1) vs general population using the coverage fraction
Study details
- Studied
- Adults dispensed teriparatide, matched to unexposed osteoporosis patients and general population patients
- Compared with
- Unexposed osteoporosis and general population cohorts
- Main outcome
- Osteosarcoma incidence
- Authors' conclusion
- Estimates were imprecise because of few cases, but osteosarcoma incidence in each cohort was within the expected background range; the evidence supported removal of the boxed warning.
- Limitations
- Very few cases; incomplete registry coverage; imprecise estimates.
-
Teriparatide-associated calciphylaxis: a case series.Humans12 peopleNo control groupCase series from literature and FDA adverse event reports through March 31, 2021
FDA and literature review found 12 cases of calciphylaxis after starting teriparatide (median age 81), one fatal; all patients had multiple other risk factors.
Key resultMedian time to onset 3.5 (range 1-20) months; three hospitalized, one death
Study details
- Studied
- Patients with calciphylaxis after teriparatide exposure of < 2 years (median age 81)
- Main outcome
- Calciphylaxis cases
- Sample
- 12 cases of teriparatide-associated calciphylaxis
- Authors' conclusion
- Teriparatide exposure together with underlying risk factors may have triggered new-onset calciphylaxis; expedited diagnosis is important.
- Limitations
- Spontaneous reports without a control group; all cases had multiple risk factors; causality not established.
Reported side effects
- uncommonNausea [ref]
- uncommonHeadache [ref]
- reportedDizziness [ref]
- reportedStopping treatment because of adverse events (more than placebo) [ref]
- rareCalciphylaxis (painful skin/vessel calcification) [ref]
- rareOsteosarcoma (isolated case; not increased in registry studies) [ref] [ref]
- reportedKidney stone [ref]
Approved prescription drug; rat studies showed bone cancer at high lifetime doses, but large human registry studies have not found an increased osteosarcoma rate.
152 registered human trials (15 active)
✓ positive · ✗ negative · ~ mixed · ? inconclusive, judged on each paper's own main outcome. Grades: A strong human evidence → D little or none. Papers and verdicts are drawn from PubMed, Europe PMC and Russian journals (CyberLeninka); not medical advice.
Registered clinical trials 152 on ClinicalTrials.gov · 15 active · 106 completed · 56 with posted results
| Trial | Status | Phase | People | Sponsor |
|---|---|---|---|---|
| Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture NCT05866029 · started 2023-05-26 |
Recruiting | – | 2,478 | Peking Union Medical College Hospital |
| To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture NCT06898060 · started 2025-06 |
Not yet recruiting | Phase 3 | 282 | Qilu Pharmaceutical Co., Ltd. |
| Preoperative Teriparatide Use on Insertional Torque of Pedicle Screws for Lumbar Fusion Surgery NCT03770338 · started 2019-03-01 |
Active, not recruiting | – | 192 | The University of Hong Kong |
| Fracture Recovery for Returning to Duty (Teriparatide STRONG) NCT04589819 · started 2022-12-08 |
Enrolling by invitation | Phase 4 | 183 | University of South Carolina |
| Sequential Therapies After Osteoanabolic Treatment NCT06164795 · started 2023-11-25 |
Recruiting | – | 150 | 424 General Military Hospital |
| Effects of Teriparatide (PTH) on Bone in Men and Women With Osteoporosis NCT01155232 · started 2004-11 |
Active, not recruiting | – | 100 | University Health Network, Toronto |
| Comparation of Treatment Strategies for OVF: Teriparatide Injection and PVP NCT03692143 · started 2017-01-01 |
Active, not recruiting | – | 90 | Nanfang Hospital, Southern Medical University |
| Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover NCT05151484 · started 2022-03-21 |
Active, not recruiting | Phase 4 | 60 | Madhumathi Rao |
| Teriparatide (PTH) and Bone Strength in Postmenopausal Women NCT01155245 · started 2008-06 |
Active, not recruiting | – | 60 | University Health Network, Toronto |
| PROactive HEALing in High-Risk Pelvic and Non-hip Lower Extremity Fragility Fractures (PRO HEAL Pilot) NCT06303284 · started 2027-03-15 |
Not yet recruiting | Phase 1, Phase 2 | 54 | University of Calgary |
| Combined Anabolic Therapy NCT06558188 · started 2025-02-03 |
Recruiting | Phase 4 | 50 | Massachusetts General Hospital |
| Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Chronic Kidney Disease NCT04522622 · started 2021-12-15 |
Recruiting | Phase 4 | 48 | Ditte Hansen |
All 152 Teriparatide trials, with countries and summaries · Search ClinicalTrials.gov · Recruiting trials for every peptide
Discussions elsewhere
Experiences and questions about Teriparatide on other sites. Treat anecdotes with care.
Teriparatide: questions people ask
What is Teriparatide?
Parathyroid hormone analog. The active first 34 amino acids of parathyroid hormone; daily injections stimulate new bone formation.
How much does Teriparatide cost?
The cheapest Teriparatide from an independently tested vendor is $1.50 per mg (Andy Peps Studio, TER10 Teriparatide 10mg * 10 vials, $150.00). Across 9 listings from 7 vendors the median is $3.05 per mg.
Where can I buy Teriparatide?
7 vendors tested by Finnrick sell Teriparatide. The cheapest per mg right now: Andy Peps Studio ($1.50), Baohua Dongnuo Biotechnology BHD ($1.50), LN Peptides ($1.50). 0 of them publish a lab report (COA) for Teriparatide; compare lab scores and reports in the table above before buying.
How much bacteriostatic water for 10 mg of Teriparatide?
Adding 2 mL of bacteriostatic water to a 10 mg vial of Teriparatide gives 5 mg/mL: each 10 units on a U-100 insulin syringe holds 500 mcg. With 1 mL it's 10 mg/mL (1,000 mcg per 10 units); with 3 mL, 3.333 mg/mL (333.3 mcg per 10 units). More water makes small amounts easier to measure. Mixing charts: 10 mg.
Is Teriparatide FDA approved?
FDA-approved as Forteo for osteoporosis.
Can Teriparatide be compounded in the US?
FDA-approved (Forteo and others) for osteoporosis. Compounding status for every peptide.
Does Teriparatide work? What does the research say?
Evidence grade A (strong human evidence), from 8 papers: Approved osteoporosis drug: large RCTs (1,637 and 1,360 women) and meta-analyses of dozens of RCTs consistently show fewer vertebral fractures. Teriparatide (PTH 1-34) is an approved osteoporosis drug backed by large human randomized trials and multiple meta-analyses showing it reduces vertebral fractures and raises bone density, including head-to-head superiority over risedronate in severe osteoporosis. The rat osteosarcoma signal has not been borne out in large human registry studies, though more people stop treatment because of side effects than on placebo. See the papers.
Are there clinical trials of Teriparatide?
ClinicalTrials.gov lists 152 registered trials of Teriparatide: 15 active, 106 completed, 33 in phase 3, 56 with posted results. Examples: Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture (Recruiting, 2,478 people); To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture (Not yet recruiting, Phase 3, 282 people); Preoperative Teriparatide Use on Insertional Torque of Pedicle Screws for Lumbar Fusion Surgery (Active, not recruiting, 192 people).
What dose of Teriparatide was used in studies?
Teriparatide is an approved drug. Forteo: 20 mcg subcutaneously once a day into the thigh or abdomen; use for more than 2 years in a patient's lifetime only considered if fracture risk remains or returns to high; postmenopausal women with prior vertebral fractures (Neer et al.): 20 or 40 microg parathyroid hormone (1-34) vs placebo once daily; postmenopausal women with severe osteoporosis and prior vertebral fractures (VERO, double-dummy vs risedronate): 20 μg teriparatide (vs risedronate 35 mg weekly) once daily. These are amounts used in published studies or official labels, not a recommendation.
What are the side effects of Teriparatide?
Reported in the research: Nausea; Headache; Dizziness; Stopping treatment because of adverse events (more than placebo); Calciphylaxis (painful skin/vessel calcification). Approved prescription drug; rat studies showed bone cancer at high lifetime doses, but large human registry studies have not found an increased osteosarcoma rate.